A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elucidation of the genetic factors underlying chronic liver disease may reveal new therapeutic targets. METHODS: We used exome sequence data and electronic health records from 46,544 participants in the DiscovEHR human genetics study to identify genetic variants associated with serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Variants that were replicated in three additional cohorts (12,527 persons) were evaluated for association with clinical diagnoses of chronic liver disease in DiscovEHR study participants and two independent cohorts (total of 37,173 persons) and with histopathological severity of liver disease in 2391 human liver samples. RESULTS: ). Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes). Associations were confirmed in two independent cohorts. The rs72613567:TA variant was associated with a reduced risk of nonalcoholic steatohepatitis, but not steatosis, in human liver samples. The rs72613567:TA variant mitigated liver injury associated with the risk-increasing PNPLA3 p.I148M allele and resulted in an unstable and truncated protein with reduced enzymatic activity. CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis. (Funded by Regeneron Pharmaceuticals and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides PNPLA3 p.I148M and TM6SF2 p.E167K, additional variants, including common risk variants in MBOAT7 , GCKR , GPAM , protective variants in HSD17B13 , APOE and MTARC1, and rare variants ( e.g. in APOB , MTTP, CIDEB and ATG7 ), have been robustly associated with the risk of progressive MASLD. 199 -205”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [200]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the periportal hepatocyte-enriched genes HSD17B13152 and PNPLA3153 are associated with NASH”
From Distinct hepatocyte identities in liver homeostasis and regeneration (2023) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some of the most important human metabolic disease genes have been identified using germline genetic methods such as GWAS and whole exome sequencing42-44.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“To demonstrate this, we examined the trans associations with a splice variant in HSD17B13 (rs72613567), known to protect against chronic liver disease42.”
From Rare variant associations with plasma protein levels in the UK Biobank (2023) · cites this paper as [42]
In the citing paper
“These findings inform the prioritization of therapeutic targets, providing clues to potential on-target side effects and opportunities for drug repurposing87–89.”
From A brief history of human disease genetics (2020) · cites this paper as [88]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Self-citationWilliams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Self-citationKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234
Self-citationYounossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord, M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,073
Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
Self-citationLiu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623
Self-citationBuch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
Cited by
Items 601–700 of 831
Deciphering 17-β-hydroxysteroid dehydrogenase 4: from molecular insights to cancer therapeutics
Liao, M.-B., Lau, A. T. Y., & Xu, Y. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03885-w · Cited by 5
CMsiRNAdb: a database of chemically modified SiRNA silencing efficiency for nucleic acid drug design
He, S., Chen, C., Pan, X., Xue, G., Yang, Y., Feng, J., Zulfiqar, H., Zhang, Y. H., & Deng, K. (2026) · BMC Bioinformatics · doi:10.1186/s12859-025-06359-y · Cited by 5
“These genes are involved in lipid metabolism (PNPLA3, PCSK9), fibrosis progression (HSD17B13), and cardiovascular diseases (AGT, LPA), among other pathological processes [36–39], suggesting that current siRNA drug development is primarily focused on the treatment of metabolic and chronic diseases.”
Liu, W., Xu, X., Chang, Q., Yang, H., Ma, Z., Zhang, T., Zhao, Y., Zhao, L., & Xia, Y. (2026) · Nutrition Journal · doi:10.1186/s12937-026-01289-8 · Cited by 4
Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan
Seko, Y., & Yamaguchi, K. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02401-9 · Cited by 4
“It mitigates liver injury in PNPLA3 I148M carriers and is associated with reduced PNPLA3 mRNA expression, suggesting a potential for targeted HSD17B13 inhibition in this subpopulation [39, 47].”
Membrane bridges and nanodomain partitioning govern membrane protein targeting to lipid droplets
Mizrak, A., Kæstel‐Hansen, J., Matthias, J., Harper, J. W., Hatzakis, N. S., Farese, R. V., & Walther, T. C. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-01963-3 · Cited by 14
“LD proteins, such as GPAT4 or HSD17B13, often contain multiple regions that can bind LDs 1,6,17 , complicating the analysis of the underlying mechanisms for membrane protein targeting.”
A data-driven framework reconstructs the molecular continuum of human MASLD progression
Kamzolas, I., Koutsandreas, T., Barker, C. G., Pournara, A. V., Weston, H., Fujiwara, N., Hoshida, Y., Anstee, Q. M., Vacca, M., Papatheodorou, I., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01543-7 · Cited by 6
“Multiple configurations of SW sizes and overlap scores (([6,15], 0.2), ([8,17], 0.25), ([8,24], 0.3), ([10,20], 0.3) and ([12,25], 0.35)), were evaluated, and the optimal path was selected across all resulting graphs (Extended Data Fig.”
InfluentialNonalcoholic Fatty Liver Disease: A Wide Spectrum Disease
Rosso, N., & Bellentani, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-24432-3_26 · Cited by 4
Genetic variation and elevated liver enzymes during childhood, adolescence and early adulthood
Stender, S., Smith, G. D., & Richardson, T. G. (2023) · International Journal of Epidemiology · doi:10.1093/ije/dyad048 · Cited by 4
Self-citationMicrobiome and Genetic Factors in the Pathogenesis of Liver Diseases
Miteva, D., Peshevska-Sekulovska, M., Snegarova, V., Peruhova, M., Vasilev, G., Vasilev, G., Sekulovski, M., Lazova, S., Gulinac, M., Tomov, L., et al. (2023) · Gastroenterology Insights · doi:10.3390/gastroent14040041 · Cited by 6
“A conducted GWAS analysis identified five previously associated variants in the MARC1 (p.Ala165Thr), PNPLA3 (p.Ile148Met), TM6SF2 (p.Glu167Lys), HSD17B13 (rs6834314), and SERPINA1 (p.Gly366Lys) gene regions [119,150].”
BackgroundPolymorphic pseudogenes in the human genome - a comprehensive assessment
Lopes‐Marques, M., Peixoto, M. J., Cooper, D. N., Prata, M. J., Azevedo, L., & Castro, L. F. C. (2024) · Human Genetics · doi:10.1007/s00439-024-02715-9 · Cited by 6
Genetic Risk Factors for Steatotic Liver Disease After Liver Transplantation
Liukkonen, V., Semenova, M., Hyvärinen, K., Lauronen, J., Partanen, J., Arola, J. T., Nordin, A. J., Färkkilä, M. A., & Åberg, F. O. (2025) · Liver International · doi:10.1111/liv.70067 · Cited by 4
“The SLD subtypes also share the most important genetic risk factors [3, 4] and thus, separating these diseases may not always be reasonable.”
Wei, A., Border, R., Fu, B., Cullina, S., Brandes, N., Jang, S.-K., Sankararaman, S., Kenny, E. E., Udler, M. S., Ntranos, V., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60339-7 · Cited by 6
“…FAME, we previously showed that genetic background modi fi es the effect of many common GWAS variants, with epistatic effects sometimes exceeding marginal effects by an order of magnitude across diverse traits, and have replicated known marginal epistasis effects such as on gene expression 23,26 .”
Sugunaraj, J. P., Brosius, H. M., Murray, M. F., Manickam, K., Stamm, J. A., Carey, D. J., & Mirshahi, U. L. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0095-6 · Cited by 4
Self-citationRNA Splicing: A Versatile Regulatory Mechanism in Pediatric Liver Diseases
Zhou, J., Zhao, Y., Wang, S., Chen, M., Zhou, S., & Chen, C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.725308 · Cited by 4
Computational Pipeline for Next-Generation Sequencing (NGS) Studies in Genetics of NASH
Salatino, A., Sookoian, S. C., & Pirola, C. J. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2128-8_16 · Cited by 4
Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development
Kemas, A. M., Youhanna, S. C., & Lauschke, V. M. (2022) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2022.2053285 · Cited by 5
“In contrast, the truncating reduced function variant rs72613567 in HSD17B13 is protective against hepatocellular injury, inflammation and fibrosis [61,62].”
BackgroundAdmixture Mapping in African Americans Identifies New Risk Loci for HCV-Related Cirrhosis
Kim, H.-S., Shetty, P. B., Tsavachidis, S., Dong, J., Amos, C. I., El‐Serag, H. B., & Thrift, A. P. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.05.020 · Cited by 4
Makino, K., Ishii, T., Ogiso, S., Nakakura, A., Nishio, T., Fukumitsu, K., Uebayashi, E. Y., Munekage, F., Horie, H., Iwaki, K., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14086 · Cited by 5
Alpha-1 Antitrypsin Z Variant (AAT PI*Z) as a Risk Factor for Intrahepatic Cholestasis of Pregnancy
Kosinski, P. D., Kędzia, M., Mostowska, A., Gutaj, P., Lipa, M., Wender-Ożegowska, E., Roży, A., Chorostowska‐Wynimko, J., Wielgoś, M., & Jezela‐Stanek, A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.720465 · Cited by 4
Striving Towards Equity in Cardiovascular Genomics Research
Vélez, J. A. J., Anderson, N., Datcher, I., Foster, C., Jackson, P., & Hidalgo, B. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01277-z · Cited by 4
The Role of (Nuclear) Lipid Droplets in the Pathogenesis of Metabolic Syndrome.
Todosenko, N., Yurova, K., Khaziakhmatova, O., Vulf, M., Malashchenko, V., Komar, A., Kozlov, I., Khlusov, I., & Litvinova, L. (2025) · Frontiers in Bioscience · doi:10.31083/fbl26742 · Cited by 2
Wang, Q., Wang, Z., Hu, M., Liu, F., & Wang, Z. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1623367 · Cited by 3
Liang, Z., Chen, L., Liao, Z., Mao, J., Liu, Y., & Li, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01825 · Cited by 3
Self-citationCiaula, A. D., Krawczyk, M. J., Weber, S. N., Khalil, M., JohnBritto, J. S., Abdallah, H., & Portincasa, P. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106555 · Cited by 4
Mărginean, I. C., Cazacu, S. M., Popescu, M., Iacob, G. A., Săndulescu, L., Iordache, S., Mărginean, C. M., & Vere, C. C. (2025) · Life · doi:10.3390/life15111764 · Cited by 6
Zhu, B. J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1753393 · Cited by 3
“Conversely, the HSD17B13 loss-of-function variant (rs72613567: TA) is associated with reduced risk of chronic liver disease and decreased progression from steatosis to steatohepatitis (28).”
Xiong, S., Hu, L., Sun, Y.-Y., Huang, W., & Hu, X.-Y. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119025 · Cited by 5
Monogenic and Polygenic Risk in Common Liver Diseases: Implications for Clinical Care
Ajmera, V. H., Huang, D. Q., Chen, V. L., & Reddy, K. R. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.03.020 · Cited by 5
Paik, J. M., Kalligeros, M., Zelber‐Sagi, S., Paik, A., Alqahtani, S. A., & Younossi, Z. M. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101888 · Cited by 4
“31,32 In both strata, T2D prevalence increased progressively across MASLD prevalence tertiles, consistent with the central role of diabetes in the structural models.”
Ko, D., Low, J. J. Y., Lőw, P., Chua, D., Dan, Y. Y., Chen, V. L., Fallowfield, J. A., Kendall, T. J., Takahashi, H., Ng, C. H., et al. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00061-3 · Cited by 5
“Comparably,riskof progressionfromsteatosistoMASHand fi brosisisdecreasedbytheloss-of-function variants in HSD17B13 (e.g., rs72613567:TA) by reducing hepatocyte lipotoxicity through altered retinol metabolism 36,37 .”
Kim, H. Y., Kim, D. J., Lee, H. A., Cho, J., & Kim, W. K. (2023) · Metabolites · doi:10.3390/metabo13030444 · Cited by 3
Kozlitina, J., Cohen, N. M., Sturtevant, D., Cohen, J. C., Murphey-Half, C., Saltarrelli, J. G., Jindra, P., Askar, M. Z., Hwang, C. S., Vagefi, P. A., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102350 · Cited by 3
“20,31 The lack of effect of heterozygous donor HSD17B13 genotype on post-LT survival may be related to the relatively smaller size of our study compared to previous studies, which looked at association with disease risk, not post-LT survival.”
BackgroundMethodResultInfluentialSelf-citationExpression and localization of HSD17B13 along mouse urinary tract
Zhang, H., Chang, J., Dai, Z., Wang, Q., Qiao, R., Huang, Y., Ma, B., Jiang, J., Zhu, C., Su, W., et al. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00069.2024 · Cited by 3
Choi, R., Vemuri, J. P., Poloju, A., Raj, R., Mehta, A., Asgharpour, A., Siddiqui, M. S., & Majety, P. (2025) · Endocrines · doi:10.3390/endocrines6020027 · Cited by 4
An ethanol-induced loss of the lipid droplet–associated segregase VCP/p97 leads to hepatic steatosis
Sen, S., Weller, S. G., Schulze, R. J., Ding, D., Casey, C. A., Weihl, C. C., & McNiven, M. A. (2025) · The Journal of Cell Biology · doi:10.1083/jcb.202408205 · Cited by 3
Diagnostic challenges in patients with alcohol-related liver disease
Krag, A. A., Roskams, T., Pinzani, M., & Mueller, S. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1713-4372 · Cited by 3
“In contrast the HSD17B13 variant seems to have protective properties against NASH and ALD [17].”
Murali, A. R., Prakash, S., & Sánchez, A. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.102066 · Cited by 3
Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions
Choudhuri, G., Shah, S., Kulkarni, A. V., Jagtap, N., Gaonkar, P. P., Desai, A. S., & Adhav, C. V. (2023) · Cureus · doi:10.7759/cureus.42852 · Cited by 4
“The risk of NASH was reduced by 14% in the presence of the HSD17B13 variant [56].”
BackgroundWang, Y., Yu, H., Cen, Z., Zhu, Y., & Wu, W. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100267 · Cited by 3
Bansal, M. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26710-9.00008-0 · Cited by 3
Chrysavgis, L., & Cholongitas, Ε. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21938-2.00020-5 · Cited by 3
Genetic Variations Linked to Hepatocellular Carcinoma: Personalized Medicine Takes a Step Forward
Agarwal, P. D., & Lucey, M. R. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0260-z · Cited by 3
Insights into paediatric non‐alcoholic fatty liver disease from genetic variants
Dong, J., Im, Y. R., & Mann, J. P. (2019) · Liver International · doi:10.1111/liv.14020 · Cited by 4
MARC1 and HNRNPUL1: Two Novel Players in Alcohol-related Liver Disease
Romeo, S. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.08.009 · Cited by 3
Schneider, C. V., Hamesch, K., & Strnad, P. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.002 · Cited by 3
Variance quantitative trait loci reveal gene-gene interactions which alter blood traitsPreprint
Pershad, Y., Poisner, H. M., Corty, R. W., Hellwege, J. N., & Bick, A. G. (2024) · medRxiv · doi:10.1101/2024.09.18.24313883 · Cited by 2
Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosityPreprint
Kim, H. I., DeBoever, C., Walter, K., Kalantzis, G., Li, C., Mozaffari, S. V., Kundu, K., Jacobs, B. M., Mohammadi‐Shemirani, P., Musolf, A. M., et al. (2025) · medRxiv · doi:10.1101/2025.06.05.25329068 · Cited by 3
A novel human hepatocyte cell line to study PNPLA3-associated steatotic liver disease
Huang, G., Wallace, D. F., & Subramaniam, V. N. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00193.2024 · Cited by 2
Zhang, C., Feng, Y., Zhang, X., Guan, Y., & Su, W. (2025) · Metabolites · doi:10.3390/metabo15060353 · Cited by 2
“Variants of the HSD17B13 gene, such as rs72613567 and rs6834314, have been linked to a lower risk of chronic liver disease progression in patients with MAFLD, including advanced fibrosis and cirrhosis [13,14].”
Fu, S., Groothuismink, Z. M. A., Balderramo, D., de Mattos, Â. Z., Hoppe, L., Carrera, E., Ferrer, J. D., Ortíz, J. E. P., Bañales, J. M., Arrese, M. A., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101508 · Cited by 3
“17,28 For the calculation of odds ratios (ORs) in these participants, a combined GRS was calculated as the sum of the risk-increasing alleles (range, 0–8).”
Transfer RNA-derived small RNAs in liver disease
Huang, Q.-Y., Zhou, Z.-Y., Zhang, Y., Zhou, Y., Duan, S., & Dong, J. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.07.001 · Cited by 6
Illuminating the mystery of thylacine extinction: a role for relaxed selection and gene loss
Salve, B. G., & Vijay, N. (2025) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2025.1339 · Cited by 4
RNA inosine sensor-guided TadA mutational scanning for toxicity minimization of adenine base editors
Zhang, C., Chen, Z., Cao, J., Zhang, Z., Li, W.-K., Zhang, X., Chen, J., Liu, J., Yuan, Z., Gao, F., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.011 · Cited by 3
Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH
Jermy, B. S., Brownrigg, J., Strnad, P., & Loomba, R. S. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102143 · Cited by 3
Gillies, C. E., Mbatchou, J. S., Habegger, L., Kessler, M. D., Bao, S., Balasubramanian, S., Delaneau, O., Kosmicki, J. A., Willer, C. J., Kang, H. M., et al. (2025) · Genetic Epidemiology · doi:10.1002/gepi.70023 · Cited by 4
Self-citationSato, S., Kawai, H., Yamaguchi, M., Nago, H., Kato, Y., Om, R., Terai, Y., Kita, Y., Ikeda, Y., Sato, S., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70136 · Cited by 2
“Notably, genetic variants such as PNPLA3 I148M, which promotes hepatic fat accumulation, and the HSD17B13 loss- of-function variants, which may mitigate hepatocellular injury, have been implicated in modulating steatosis and disease severity independently of ALT levels [27, 28].”
HSD17β11 regulates PLIN5-ATGL mediated lipolysis, but not hepatic lipid metabolism in mice
Keenan, S. N., Suriani, N. D., Fidelito, G., Bayliss, J., Lou, J., Solano, A. N., Sacharz, J., Stroud, D. A., Bezawork‐Geleta, A., Ooi, G., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100943 · Cited by 2
Zhang, Y., Xiong, C., Jiang, Z., Wang, X., Wang, Z.-H., Chen, J., Li, Q., Luo, Y., Yang, X., Chu, C., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03649-w · Cited by 2
“Furthermore, speci fi c polymorphisms in the HSD17B13 gene have been associated with varying risks of HCC, highlighting its potential role in patient strati fi cation and personalized therapy [55, 56].”
Évolution de la nomenclature des maladies hépatiques stéatosiques : vers un changement de paradigme
Halfon, P. (2025) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2025.12.003 · Cited by 2
Liang, Z., Jin, H., Gao, W., Zhang, H., Hu, X., Li, R., Li, X., Cheng, Y., Guo, L., & Liu, Y. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00677 · Cited by 2
Self-citationRaghavan, R. P., Alexander, K. T., Sadasivan, S., Parmar, C. D., & Kathirvel, M. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16010029 · Cited by 4
Tomar, N., Choudhury, S., Arora, A., Sharma, P., Vaibhav, R., Hasan, R., Jan, S., Kaur, R., Rajput, T., Lomada, M. S., et al. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103638 · Cited by 2
Kobayashi, T., Yoneda, M., Duseja, A., Fan, J.-G., Nersesov, A., & Nakajima, A. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.010 · Cited by 3
Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment
Kozlitina, J., Romeo, S., & Hobbs, H. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001758 · Cited by 2
Self-citationZhu, G., Zhao, Q., Ran, J., Zhang, H., Yin, S., Issa, R., Shi, J., Wu, C., & Li, J. (2026) · Communications Medicine · doi:10.1038/s43856-026-01651-1 · Cited by 3
Zhu, B., He, N., Xiao, Y., Chen, B., Li, C., Mandla, R., Liu, Y., Zhang, J., Chang, X., Yu, F., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02617-8 · Cited by 5
“3h) 34 .”
Self-citationFNIP1 variants are associated with favourable metabolism in 1 million humans
Hindy, G., Adam, R. C., Sosina, O. A., Pryce, D. S., Blair, D., Herman, J., Lee, J., Dornbos, P., Mayerhofer, E., Gilly, A., et al. (2026) · Nature · doi:10.1038/s41586-026-10864-2 · Cited by 3
“Among the 18 genes with both gene-burden and common variant liver eQTL evidence, 15 showed directional concordance, whereby the liver-expression-lowering allele was associated with the TG:HDL ratio in the same direction as the rare deleterious coding variants (observed percentage, 83%; expected…”
Self-citationMolecular mechanisms and pathogenesis of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10529-0 · Cited by 9
“This leads to reduced oxidation of retinol to retinal in an NADH-dependent reaction 33,64 .”
InfluentialSmirnova, O. V., & Владимировна, Л. Д. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2022-026 · Cited by 2
Khan, M. Q., Hassan, S. M., Lizaola‐Mayo, B., Bhat, M., & Watt, K. D. S. (2023) · Hepatology · doi:10.1097/hep.0000000000000674 · Cited by 3
Genetic predisposition to metabolic dysfunction-associated fatty liver disease
Абатуров, А. Е., & Нікуліна, А. О. (2024) · CHILD`S HEALTH · doi:10.22141/2224-0551.19.3.2024.1696 · Cited by 3
Lemasters, J. J., & Zhong, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15260-3.00026-0 · Cited by 3
Measuring HSD17β13 protein turnover in mouse liver with D 2 O metabolic labeling and hybrid LC-MS
Shi, Y., Rosario, A. M. D., Wang, S.-P., Kang, L., Liu, H., Rady, B., & Jian, W. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2452757 · Cited by 2
The Natural History of NAFLD: Environmental vs. Genetic Risk Factors
Valenti, L. V. C., & Pelusi, S. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_7 · Cited by 2
Clinical approach to liver disease in adults with AATD
Strnad, P., Schneider, C. V., & Clark, V. (2019) · European Respiratory Society eBooks · doi:10.1183/2312508x.10033018 · Cited by 2
Dual proteotoxic stress accelerates liver injury via activation of p62‐Nrf2
Kuscuoglu, D., Bewersdorf, L., Wenzel, K., Groß, A., Ensari, G. K., Luo, Y., Kilic, K., Hittatiya, K., Golob‐Schwarzl, N., Leube, R. E., et al. (2021) · The Journal of Pathology · doi:10.1002/path.5643 · Cited by 6
“Although the importance of PiZ for the progression of ALD/ NAFLD-related liver disease has been firmly established [15,16], only cohorts with limited size have addressed its relevance in other disorders such as hemochromatosis or chronic viral hepatitis [2].”
BackgroundScience, serendipity, and the single degree
Hobbs, H. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci124404 · Cited by 3
“Together with Regeneron, we recently reported a variant that is not associated with hepatic steatosis in the Dallas Heart Study and yet protects against the progression of FLD (56).”
Self-citationObesity and non-alcoholic fatty liver disease: therapeutic options
Kaschenko, V., Mitsinskaya, A. I., Sokolov, A. Y., Шишкин, А. Н., Varzin, S. A., Neymark, A. E., Насрединович, М. С., Lodygin, A. V., Mitsinskiy, M., & Akhmetov, A. D. (2020) · Siberian medical review · doi:10.20333/2500136-2020-3-20-29 · Cited by 3
NAFLD/NASH-Related Hepatocellular Carcinoma: Along with the Role of Genetics
Fujioka, K. (2020) · Open Access Journal of Cancer & Oncology · doi:10.23880/oajco-16000165 · Cited by 2
Galmozzi, E. (2019) · Hepatology · doi:10.1002/hep.31044 · Cited by 2
“Finally, because the presence of the HSD17B13 G-insertion transcript has been described only in one other article to date,(5) this new mechanism of alternative splicing needs further validations.”
BackgroundA Polymorphism in the FGF21 Gene is a Novel Risk Variant for Metabolic-Associated Steatohepatitis
Elsayed, A. (2020) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 3
Editorial: PNPLA3 genotype and liver diseases—more than non‐alcoholic fatty liver disease
Huang, J., & Chuang, W. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15788 · Cited by 2
Kabbani, M., Michailidis, E., Steensels, S., Fulmer, C. G., Luna, J. M., Pen, J. L., Tardelli, M., Razooky, B. S., Ricardo-Lax, I., Zou, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.19.387613 · Cited by 2
Non-Alcoholic Fatty Liver Disease and Steatohepatitis
Govaere, O., & Anstee, Q. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00265-0 · Cited by 2
Jabalameli, M. R., Holmes, M. V., Hinds, D. A., Auton, A., & Fontanillas, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.15.608197 · Cited by 4
The Genetics of Alcohol-Related Liver Disease
Innes, H. A., & Stickel, F. (2023) · Springer eBooks · doi:10.1007/978-3-031-32483-3_52 · Cited by 2
Choudhuri, G., Kalel, S. R., Sharma, Z. D., & Bansal, R. (2024) · Gastroenterology & Hepatology Open Access · doi:10.15406/ghoa.2024.15.00585 · Cited by 3
Ferrari, C., Ashraf, B., Saeed, Z. H., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15040066 · Cited by 1
Wang, J., Ding, D., Shao, X., Ma, L., Xu, J., Melehani, J. H., Boyette, L. B., Watkins, T. R., Jia, C., Malkov, V. A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16443 · Cited by 1
Rutledge, S. M., & Brown, R. S. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.09.005 · Cited by 2
Metabolic and Alcohol-Associated
Sandella, R., & Rinella, M. E. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.09.003 · Cited by 2
MASLD – Krankheitslast, Herausforderungen und neue Therapeutika
Roeb, E. (2025) · Die Gastroenterologie · doi:10.1007/s11377-025-00868-1 · Cited by 1
“K Schwerpunkt member 1“ ( SLC2A1 ) und „17-β hydroxy-steroid dehydrogenase 13“ ( HSD17B13 ) für die MASLD-Ausprägung von Bedeutung zu sein [13].”
Pandovski, S., Yang, T., Zhou, H. H., Rosahl, T. W., Carballo‐Jane, E., Talukdar, S., & Coyne, E. S. (2026) · Biochemical Journal · doi:10.1042/bcj20253411 · Cited by 2
“…13 ( HSD17B13 ), the p.I148M missense variant in Patatin-like Phospholipase Domain Containing 3 ( PNPLA3 ), the p.E167K missense variant in Transmembrane 6 Superfamily Member 2 ( TM6SF2 ), and the p.G17E missense variant in Membrane-Bound O-acyltransferase domain-containing 7 ( MBOAT7 ) [12– 15].”
Ji, X., Wang, Y., Li, L., Yang, H., Ma, Z., Wang, C., Zhao, Y., Ding, Y., & Xia, Y. (2026) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70372 · Cited by 1
Sehrawat, T. S., Cooper, S. A., Navarro‐Corcuera, A., Schulze, R. J., Liu, M., Yaqoob, U., Yeon, Y., Yoon, S., Noh, Y., Meroueh, C., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-39913-6 · Cited by 1
Dohnalová, K., Kamaraj, R., Ambrož, M., Klíma, K., Chalupský, K., Bajnokova, M., Mejdrová, I., Škach, K., Hricová, J., Laštůvková, H., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119168 · Cited by 1
Metabolic dysfunction-associated steatotic liver disease in Asia: implications on management
Lai, K. N., & Wong, V. W. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-167 · Cited by 2
Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease
Davidson, N. O. (2026) · Circulation Research · doi:10.1161/circresaha.126.327269 · Cited by 2
Steatotic liver disease in Latin America: current views and perspectives
Idalsoaga, F. J., Díaz, L. A., Francisco Barrera, M., Gadano, A. C., de Oliveira, C. P. M. S., Arab, J. P., & Arrese, M. A. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01219-3 · Cited by 1
“Carriers of the HSD17B13 protective allele have shown a 30–50% reduced risk of progressing from steatosis to advanced fibrosis in both MASLD and ALD 64 .”
InfluentialVishnubhotla, R., Govardhan, B., Kulkarni, A. V., Reddy, D. N., & Rao, P. N. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103616 · Cited by 1
Metadata
- Authors
- Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., Stepanchick, A. N., Still, M. D., McCarthy, S., O’Dushlaine, C., Packer, J. S., Balasubramanian, S., Gosalia, N., Esopi, D., Kim, S. Y., Mukherjee, S., Lopez, A. E., Fuller, E. D., Penn, J., Chu, X., Luo, J. Z., Mirshahi, U. L., Carey, D. J., Still, C. D., Feldman, M. D., Small, A., Damrauer, S. M., Rader, D. J., Zambrowicz, B., Olson, W., Murphy, A. J., Borecki, I. B., Shuldiner, A. R., Reid, J. G., Overton, J. D., Yancopoulos, G. D., Hobbs, H. H., Cohen, J. C., Gottesman, O., Teslovich, T. M., Baras, A., Mirshahi, T., Gromada, J., & Dewey, F. E.
- Affiliations
- From the Regeneron Genetics Center (N.S.A.-H., A.H.L., C.S., S. McCarthy, C.O., J.S.P., S.B., N.G., S. Mukherjee, A.E.L., E.D.F., J.P., I.B.B., A.R.S., J.G.R., J.D.O., O.G., T.M.T., A.B., F.E.D.) and Regeneron Pharmaceuticals (X. Cheng, Y.X., P.S., Y.L., D.E., S.Y.K., B.Z., W.O., A.J.M., G.D.Y., J.G.), Tarrytown, NY; the University of Texas Southwestern Medical Center at Dallas, Dallas (J.K., S.S., H.H.H., J.C.C.); and Geisinger Health System, Danville (G.C.W., A.N.S., M.D.S., X. Chu, J.Z.L., U.L.M....
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Geisinger Health System (US)
- University of Pennsylvania (US)
- ORCID
- Cheng, Xiping
- Li, Alexander H.
- Xin, Yurong
- Schurmann, Claudia
- Liu, Yashu
- Kozlitina, Julia
- Stender, Stefan
- Wood, G. Craig
- Still, Matthew D.
- O’Dushlaine, Colm
- Packer, Jonathan S.
- Balasubramanian, Suganthi
- Gosalia, Nehal
- Esopi, David
- Kim, Sun Y.
- Mukherjee, Semanti
- Lopez, Alexander E.
- Chu, Xin
- Luo, Jonathan Z.
- Mirshahi, Uyenlinh L.
- Carey, David J.
- Still, Christopher D.
- Feldman, Michael D.
- Small, Aeron
- Damrauer, Scott M.
- Rader, Daniel J.
- Zambrowicz, Brian
- Olson, William
- Murphy, Andrew J.
- Borecki, Ingrid B.
- Shuldiner, Alan R.
- Reid, Jeffrey G.
- Overton, John D.
- Hobbs, Helen H.
- Cohen, Jonathan C.
- Baras, Aris
- Mirshahi, Tooraj
- Gromada, Jesper
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03-22
- Volume
- 378
- Issue
- 12
- Pages
- 1096-1106
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6668033
- OpenAlex
- W2793543636
- Cited by
- 827
- References
- 32
- Citations by year
- 2026: 101 · 2025: 104 · 2024: 82 · 2023: 104 · 2022: 100 · 2021: 109 · 2020: 127 · 2019: 67 · 2018: 32
- FWCI
- 48.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Regeneron Pharmaceuticals
- Perelman School of Medicine, University of Pennsylvania
- Smilow Foundation
- National Institutes of Health (P30DK072488, UL1TR001105)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- HSD17B13, chronic liver disease, loss-of-function mutations, alcoholic liver disease, non-alcoholic liver disease, alcoholic cirrhosis, non-alcoholic cirrhosis, nonalcoholic steatohepatitis, steatosis, alanine aminotransferase, aspartate aminotransferase, PNPLA3, liver histopathology
- MeSH terms
- Exome Sequencing, Loss of Function Mutation, Alanine Transaminase, Aspartate Aminotransferases, Chronic Disease, Fatty Liver, Female, Genotype, Humans, Liver, Liver Diseases, Male, Genetic Variation, 17-Hydroxysteroid Dehydrogenases, Biomarkers, Linear Models, Sequence Analysis, RNA, Disease Progression, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.